Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 4/2016

01-04-2016 | Original Article

RRP12 is a crucial nucleolar protein that regulates p53 activity in osteosarcoma cells

Authors: Young Joon Choi, Hye Won Lee, Yun Sun Lee, Da Mi Shim, Sung Wook Seo

Published in: Tumor Biology | Issue 4/2016

Login to get access

Abstract

RRP12 (ribosomal RNA processing 12 homolog), a nucleolar protein, plays important roles in cell cycle progression and the response to deoxyribonucleic acid (DNA) damage in yeast cells. However, its role has not been investigated in mammalian cells that possess p53, which has close functional association to nucleolus. We explored the role of RRP12 in nucleolar stress condition using an osteosarcoma cell line, U2OS. To induce DNA damage and nucleolar disruption, two cytotoxic drugs, doxorubicin and actinomycin D were used. Cytotoxic stress resulted nucleolar disruption induced cell cycle arrest and apoptosis in U2OS cells. However, RRP12 overexpression promoted resistance to cytotoxic stress. In contrast, RRP12 silencing enhanced susceptibility to cytotoxic stress. During drug treatment, p53 activity and cell death were suppressed by RRP12 overexpression but promoted by RRP12 silencing. This study demonstrated that RRP12 was crucial for cell survival during cytotoxic stress via the repression of p53 stability. Thus, targeting RRP12 may enhance chemotherapeutic effect in cancers.
Literature
1.
Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, et al. Mutational landscape and significance across 12 major cancer types. Nature. 2013;502:333–9.CrossRefPubMedPubMedCentral
2.
3.
4.
5.
6.
Andersen JS, Lyon CE, Fox AH, Leung AK, Lam YW, Steen H, et al. Directed proteomic analysis of the human nucleolus. Curr Biol CB. 2002;12:1–11.CrossRefPubMed
7.
Oeffinger M, Dlakic M, Tollervey D. A pre-ribosome-associated heat-repeat protein is required for export of both ribosomal subunits. Genes Dev. 2004;18:196–209.CrossRefPubMedPubMedCentral
8.
Vanrobays E, Leplus A, Osheim YN, Beyer AL, Wacheul L, Lafontaine DL. Tor regulates the subcellular distribution of dim2, a kh domain protein required for cotranscriptional ribosome assembly and pre-40s ribosome export. RNA. 2008;14:2061–73.CrossRefPubMedPubMedCentral
9.
Dosil M. Ribosome synthesis-unrelated functions of the preribosomal factor rrp12 in cell cycle progression and the DNA damage response. Mol Cell Biol. 2011;31:2422–38.CrossRefPubMedPubMedCentral
10.
Kalita K, Makonchuk D, Gomes C, Zheng JJ, Hetman M. Inhibition of nucleolar transcription as a trigger for neuronal apoptosis. J Neurochem. 2008;105:2286–99.CrossRefPubMedPubMedCentral
11.
Avitabile D, Bailey B, Cottage CT, Sundararaman B, Joyo A, McGregor M, et al. Nucleolar stress is an early response to myocardial damage involving nucleolar proteins nucleostemin and nucleophosmin. Proc Natl Acad Sci USA. 2011;108:6145–50.CrossRefPubMedPubMedCentral
12.
Huang M, Itahana K, Zhang Y, Mitchell BS. Depletion of guanine nucleotides leads to the mdm2-dependent proteasomal degradation of nucleostemin. Cancer Res. 2009;69:3004–12.CrossRefPubMedPubMedCentral
13.
14.
Derenzini M, Montanaro L, Trere D. What the nucleolus says to a tumour pathologist. Histopathology. 2009;54:753–62.CrossRefPubMed
15.
Trere D, Borzio M, Morabito A, Borzio F, Roncalli M, Derenzini M. Nucleolar hypertrophy correlates with hepatocellular carcinoma development in cirrhosis due to hbv infection. Hepatology. 2003;37:72–8.CrossRefPubMed
16.
Dai MS, Lu H. Inhibition of mdm2-mediated p53 ubiquitination and degradation by ribosomal protein l5. J Biol Chem. 2004;279:44475–82.CrossRefPubMed
17.
Zhang Q, Xiao H, Chai SC, Hoang QQ, Lu H. Hydrophilic residues are crucial for ribosomal protein l11 (rpl11) interaction with zinc finger domain of mdm2 and p53 protein activation. J Biol Chem. 2011;286:38264–74.CrossRefPubMedPubMedCentral
18.
Sasaki M, Kawahara K, Nishio M, Mimori K, Kogo R, Hamada K, et al. Regulation of the mdm2-p53 pathway and tumor growth by pict1 via nucleolar rpl11. Nat Med. 2011;17:944–51.CrossRefPubMedPubMedCentral
19.
Zhang Y, Wolf GW, Bhat K, Jin A, Allio T, Burkhart WA, et al. Ribosomal protein l11 negatively regulates oncoprotein mdm2 and mediates a p53-dependent ribosomal-stress checkpoint pathway. Mol Cell Biol. 2003;23:8902–12.CrossRefPubMedPubMedCentral
20.
Dai MS, Zeng SX, Jin Y, Sun XX, David L, Lu H. Ribosomal protein l23 activates p53 by inhibiting mdm2 function in response to ribosomal perturbation but not to translation inhibition. Mol Cell Biol. 2004;24:7654–68.CrossRefPubMedPubMedCentral
21.
Zhang Y, Shi Y, Li X, Du W, Luo G, Gou Y, et al. Inhibition of the p53-mdm2 interaction by adenovirus delivery of ribosomal protein l23 stabilizes p53 and induces cell cycle arrest and apoptosis in gastric cancer. J Gene Med. 2010;12:147–56.CrossRefPubMed
22.
Chen D, Zhang Z, Li M, Wang W, Li Y, Rayburn ER, et al. Ribosomal protein s7 as a novel modulator of p53-mdm2 interaction: binding to mdm2, stabilization of p53 protein, and activation of p53 function. Oncogene. 2007;26:5029–37.CrossRefPubMed
Metadata
Title
RRP12 is a crucial nucleolar protein that regulates p53 activity in osteosarcoma cells
Authors
Young Joon Choi
Hye Won Lee
Yun Sun Lee
Da Mi Shim
Sung Wook Seo
Publication date
01-04-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 4/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-4062-2

Other articles of this Issue 4/2016

Tumor Biology 4/2016 Go to the issue

Original Article

CXCL5 is a potential diagnostic and prognostic marker for bladder cancer patients

Original Article

Exosomes decrease sensitivity of breast cancer cells to adriamycin by delivering microRNAs

Original Article

Overexpression of HPV16 E6/E7 mediated HIF-1α upregulation of GLUT1 expression in lung cancer cells

Original Article

Tagging staphylococcal enterotoxin B (SEB) with TGFaL3 for breast cancer therapy

Original Article

Deregulation of miR-1, miR486, and let-7a in cytogenetically normal acute myeloid leukemia: association with NPM1 and FLT3 mutation and clinical characteristics

Original Article

Abnormality of Wnt3a expression as novel specific biomarker for diagnosis and differentiation of hepatocellular carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits